Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years

Background. Mass vaccination campaigns of the population aged 1–29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African meningitis belt countries has resulted in the near-disappearance of MenA. The vaccine was tested in clinical trials in Africa and in...

Descripción completa

Detalles Bibliográficos
Autores principales: Diallo, Aldiouma, Sow, Samba O., Idoko, Olubukola T., Hirve, Siddhivinayak, Findlow, Helen, Preziosi, Marie-Pierre, Elie, Cheryl, Kulkarni, Prasad S., Parulekar, Varsha, Diarra, Bou, Cheick Haidara, Fadima, Diallo, Fatoumata, Tapia, Milagritos, Akinsola, Adebayo K., Adegbola, Richard A., Bavdekar, Ashish, Juvekar, Sanjay, Chaumont, Julie, Martellet, Lionel, Marchetti, Elisa, LaForce, Marc F., Plikaytis, Brian D., Enwere, Godwin C., Tang, Yuxiao, Borrow, Ray, Carlone, George, Viviani, Simonetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639491/
https://www.ncbi.nlm.nih.gov/pubmed/26553684
http://dx.doi.org/10.1093/cid/civ518

Ejemplares similares

Ejemplares similares